Use of Continuous Glucose Monitors in Publicly-Insured Youth With Type 2 Diabetes - A Pilot and Feasibility Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Number of Participants With at Least 75% Wear Time Over 14 Days as a Measure of Sustained CGM Use
研究概览
简要总结
The purpose of this pilot feasibility study is to provide continued CGM access to youth with type 2 diabetes and collect descriptive data about feasibility of use of CGM in youth with type 2 diabetes ages 4 years and older. From this study the investigators hope to learn if CGM use in youth with type 2 diabetes can be tolerated and sustained with good adherence and to describe blood glucose patterns in youth with type 2 diabetes. The primary aim will be to evaluate the feasibility of CGM start and continuation in youth with T2D and describe glucose metrics and patient reported outcomes (PROs). The investigators will pilot and refine a program to test the hypothesis that CGM start and continuation in youth with T2D is feasible and then evaluate glucose metrics and PROs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 19 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •public insurance
- •between ages 4-19.99 years inclusive
- •diagnosis of T2D (diabetes autoantibody negative) followed in the Pediatric Endocrinology clinic at Stanford Children's Health
- •HbA1C greater than 6.5% at enrollment
- •interested in starting on a continuous glucose monitor
- •have access to a mobile device that is compatible with CGM applications or willing to use CGM receiver provided
排除标准
- •non-T2D diagnosis
- •HgA1C < 6.5%
- •are not willing to wear CGM
- •have private health insurance.
结局指标
主要结局
Number of Participants With at Least 75% Wear Time Over 14 Days as a Measure of Sustained CGM Use
时间窗: months 2,3,6,9 and 12 (assessed over the 14 days prior to each clinic visit)
次要结局
- PROMIS Global Health Overall Scale Score(baseline, months 3 and 12)
- Time With Glucose Values in Target Range of 70-180 mg/dL(months 2,3,6,9 and 12 (assessed over the 14 days prior to each clinic visit))
- PedsQL 3.2 Scale Score - Parent Rated(baseline and months 3 and 12)
- Problem Areas in Diabetes (P-PAID) Overall Scale Score - Parent Rated(baseline, months 3 and 12)
- Mean HbA1C(baseline and months 2,3,6,9 and 12)
- PedsQL 3.2 Overall Scale Score - Participant Rated(baseline and months 3 and 12)
- Diabetes Technology Attitudes (DTA) - Participant Rated(1 year (assessed at baseline, 3 months and 12 months))
- Problem Areas in Diabetes-Teen Version (PAID-T) Overall Scale Score - Participant Rated(baseline, months 3 and 12)
- Diabetes Technology Attitudes (DTA) - Parent Rated(1 year (assessed at baseline, 3 months and 12 months))
研究者
Sejal Shah
Clinical Assistant Professor of Pediatrics
Stanford University